Ongoing prospective trials
Poster Session 16
-
Location:Room Vienna, North Hall (Level 1)
-
Chairs:
-
Aims and objectives of this session To show what is currently going on in oncologic urology and other fields in urology regarding multicentre prospective randomized studies.
- Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
Institutes: 1Massachusetts General Hospital Cancer Center and Harvard Medical School, Dept. of Urologic Oncology, Boston, United States of America, 2University of Montreal, University of Montreal Hospital Center/CRCHUM, Montreal, Canada, 3Northwestern University Feinberg School of Medicine, Dept. of Hematology/Oncology, Chicago, United States of America, 4San Camillo and Forlanini Hospitals, Dept. of Medical Oncology, Rome, Italy, 5Gustave Roussy, University of Paris Sud, Cancer Medicine, Villejuif, France, 6University of Colorado, Dept. of Urologic Oncology, Aurora, United States of America, 7Bayer Pharmaceuticals, Dept. of Oncology, Whippany, United States of America, 8Bayer Pharma AG, Dept. of Oncology, Berlin, Germany, 9Cancer Centre, Catholic University of Louvain (UCL), Dept. of Urology, Brussels, Belgium
Institutes: 1University College London, Dept. of Surgery and Interventional Science – Centre For Molecular Intervention, London, United Kingdom, 2University College London, UCL Centre For Medical Imaging, London, United Kingdom, 3University College London, Dept. of Surgery and Interventional Science, London, United Kingdom, 4Cancer Research UK, Translational Cancer Therapeutics Laboratory, London, United Kingdom, 5University College London, Cancer Institute, London, United Kingdom, 6Institute of Cancer Research, Centre For Evolution and Cancer, London, United Kingdom, 7University College London, Dept. of Research Pathology, London, United Kingdom, 8University College London, UCL Centre For Medical Image Computing, London, United Kingdom, 9Institute of Cancer Research, Dept. of Clinical Studies, London, United Kingdom
Institutes: 1Merck & Co., Inc., Dept. of Clinical Oncology, Kenilworth, United States of America, 2Seattle Cancer Care Alliance, Dept. of Medicine, Seattle, United States of America
Institutes: 1King’s College London, Mrc Centre For Transplantation, London, United Kingdom, 2King’s College London, MRC Centre For Transplantation, London, United Kingdom, 3Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, 4OLV Clinic, Dept. of Urology, Aalst, Belgium
Institutes: 1Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Fondazione IRCCS – Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, 3Fondazione IRCCS – Istituto Nazionale Dei Tumori, Human Tumors Immunobiology Unit, Milan, Italy, 4Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Pharmacy Unit, Milan, Italy, 5Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, 6Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, 7Fondazione IRCCS – Istituto Nazionale Dei Tumori, Nuclear Medicine and PET Unit, Milan, Italy
Institutes: 1Technical University of Munich, Dept. of Urology, Munich, Germany, 2Bladder Cancer Center, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, United States of America, 3Hospital Universitario 12 De Octubre, Dept. of Oncology, Madrid, Spain, 4University of Southern California, Dept. of Oncology, Los Angeles, United States of America, 5Northwestern University, Dept. of Oncology, Chicago, United States of America, 6University of Tsukuba, Dept. of Oncology, Ibaraki, Japan, 7Barts Cancer Institute, Queen Mary University of London, London, United Kingdom, 8Genentech, Inc., Dept. of Oncology, South San Francisco, United States of America, 9Roche, Dept. of Oncology, Basel, Switzerland, 10Hôpital Saint-Louis, Dept. of Oncology, Paris, France
Institutes: 1Texas Oncology, Dallas, United States of America, 2Eisai, Woodcliff Lake, United States of America, 3Eisai, OBG, Woodcliff Lake, United States of America, 4H. Lee Moffitt, Cancer and Research Center, Tampa, United States of America
Institutes: 1Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2Fondazione IRCCS – Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, 3Fondazione IRCCS – Istituto Nazionale Dei Tumori, Human Tumors Immunobiology Unit, Milan, Italy, 4Fondazione IRCCS – Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, 5Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, 6Fondazione IRCCS – Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, 7Fondazione IRCCS – Istituto Nazionale Dei Tumori, Nuclear Medicine and PET Unit, Milan, Italy
Institutes: 1University of Southampton, Dept. of Health Sciences, Southampton, United Kingdom, 2Bristol Urological Institute, Dept. of Learning and Research, Bristol, United Kingdom, 3University of Alberta, Faculty of Nursing, Alberta, Canada, 4University College London, Continence & Skin Technology Group, London, United Kingdom